Preventive effect of Rikkunshito, a traditional Japanese medicine, on chemotherapy-induced nausea and vomiting with cisplatin: Case series

2Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Aim: Supportive therapies are important to treat chemotherapy-induced nausea and vomiting (CINV). Rikkunshito, a Kampo medicine, has been reported to be effective against cisplatin-induced anorexia in rats. In the present study, we evaluated the preventive effect of Rikkunshito for CINV in patients receiving high-dose cisplatin chemotherapy. Methods: We selected patients who received chemotherapy including cisplatin (≥60 mg/m2) for gastric or esophageal cancer between April 2010 and August 2012. We identified 20 patients treated without a reduction in the dose of anticancer medications during the second course and added 7.5 g/day Rikkunshito, which was orally administered, for 7 days. All patients were treated with 5-hydroxytryptamine-3 receptor antagonist, corticosteroid, and neurokinin-1 receptor antagonist for the prevention of CINV during the first and second courses. We evaluated complete response (CR; defined as no emesis and no rescue medication) and other toxicities according to the Common Terminology Criteria for Adverse Events version 4.0. Results: The median patient age was 63 years (range, 49–77 years). The chemotherapy regimens used were cisplatin plus 5-fluorouracil in 15 patients with esophageal cancer and cisplatin plus S-1 in five patients with gastric cancer. Rate of delayed CR was 75.0% during the first course (95% CI: 56.0–94.0%), which improved during the second course to 95.0% (95% CI: 85.4–100%, P = 0.077). There was no significant difference in other major toxicities between the first and second courses. Conclusion: Rikkunshito has the potential to alleviate CINV in patients receiving high-dose cisplatin chemotherapy.

References Powered by Scopus

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial

6211Citations
N/AReaders
Get full text

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

1916Citations
N/AReaders
Get full text

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group

741Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Medicinal herbs in treating chemotherapy-induced nausea and vomiting: A review

8Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kajiura, S., Hosokawa, A., Yoshita, H., Ueda, A., Ando, T., Fujinami, H., … Sugiyama, T. (2015). Preventive effect of Rikkunshito, a traditional Japanese medicine, on chemotherapy-induced nausea and vomiting with cisplatin: Case series. Traditional and Kampo Medicine, 2(1), 8–13. https://doi.org/10.1002/tkm2.1012

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 1

50%

Researcher 1

50%

Readers' Discipline

Tooltip

Medicine and Dentistry 2

67%

Economics, Econometrics and Finance 1

33%

Save time finding and organizing research with Mendeley

Sign up for free